審議結果報告書 メチレンブルー静注 50 mg「第一三共」 (Review report, Methylene Blue IV 50 mg ‘Daiichi Sankyo’) (2014)

Government Record · 医薬食品局審査管理課 / 独立行政法人医薬品医療機器総合機構 (Pharmaceuticals and Medical Devices Agency, PMDA) · November 26, 2014

医薬食品局審査管理課 / 独立行政法人医薬品医療機器総合機構 (Pharmaceuticals, 2014-11-26: PMDA's review report for Methylene Blue IV 50 mg 'Daiichi Sankyo' (applicant 第一三共株式会社, filed 14 March 2014) records the approved indication as 中毒性メトヘモグロビン血症 (toxic methemoglobinemia), changed from the applied-for 後天性メトヘモグロビン血症, and finds efficacy expected and safety acceptable.

本剤の効能・効果は、「中毒性メトヘモグロビン血症」とすることが適当と考える。

p. 36 (PDF page 36)

医薬食品局審査管理課 / 独立行政法人医薬品医療機器総合機構 (Pharmaceuticals, 2014-11-26: PMDA's review report for Methylene Blue IV 50 mg 'Daiichi Sankyo' (applicant 第一三共株式会社, filed 14 March 2014) records the approved indication as 中毒性メトヘモグロビン血症 (toxic methemoglobinemia), changed from the applied-for 後天性メトヘモグロビン血症, and finds efficacy expected and safety acceptable. C7 – Japan. non-Latin quote, hand-check (Japanese). Original title: 審議結果報告書 メチレンブルー静注 50 mg「第一三共」. English translation of the quoted field: 'Indication: toxic (poisoning-induced) methemoglobinemia'. Record fields from the same PDF: 販売名 メチレンブルー静注 50 mg「第一三共」; 一般名 メチルチオニニウム塩化物水和物; 申請者名 第一三共株式会社; 申請年月日 平成26年3月14日 (2014-03-14); 申請区分 医療用医薬品(1)新有効成分含有医薬品; 薬事・食品衛生審議会薬事分科会 第一部会 2014-11-21 found no obstacle to approval; 再審査期間 8 years; 原体 毒薬, 製剤 劇薬. Confidence MEDIUM because the quoted indication is a transcribed record field (indication text, not prose) and the approval date itself is taken from the company release in the next row, not from this document. Fetch route: curl + pdftotext -layout. Excerpt replaced during assembly: the first pass quoted the approval table, where pdftotext interleaves the two adjacent column heads ("[効能・効果][用法・用量]"), so the quote spanned a column break. The row now quotes one contiguous sentence from the review's discussion of the indication, page 36. Translation: "The efficacy and effect of this product should appropriately be stated as 'toxic methemoglobinemia'." non-Latin quote, hand-check. Study type: regulatory record.